TLIS Reminder: Kessler Topaz Meltzer & Check, LLP – March 8, 2022 Lead Plaintiff Deadline Reminder for Talis Biomedical Corporation Investors – QNT Press Release

[ad_1]

RADNOR, Pa., Feb. 19, 2022 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Talis Biomedical Corporation (“Talis”) (NASDAQ:TLIS). The action charges Talis with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Talis’ materially misleading statements to the public, Talis investors have suffered significant losses.

Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE

CLICK HERE TO SUBMIT YOUR TALIS LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER:
https://www.ktmc.com/talis-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=talis

LEAD PLAINTIFF DEADLINE: March 8, 2022

CLASS PERIOD: February 12, 2021 through January 7, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com

TALIS’ ALLEGED MISCONDUCT
Talis develops diagnostic tests to enable accurate, reliable, low cost, and rapid molecular testing for infectious diseases. Specifically, the Talis One tests are being developed for respiratory infections, infections related to women’s health, and sexually transmitted infections. In its Registration Statement, Talis disclosed that in January 2021the company submitted a request for an Emergency Use Authorization (“EUA”) to the US …

Full story available on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center